RxDoctor Payments Data

Caroline Mauldin

Acute Care · Huntsville, ALNPI 1457597080

Payments from drug & device makers

$6,550in general payments, 2019–2025

Across 125 payments — averaging $52.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$2K
  • E.r. Squibb & Sons, L.L.C.$423
  • Boehringer Ingelheim$357
  • United Therapeutics Corporation$327
  • Actelion Pharmaceuticals US, Inc.$293
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$2,38836%
  • Food & beverage$4,16164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,550 in reported general payments places this provider in the 90th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$21,491
Medicare patients
162
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin83$87,045
EntrestoSacubitril/Valsartan53$65,496
EliquisApixaban32$27,453
FarxigaDapagliflozin Propanediol18$19,177
OzempicSemaglutide18$14,269
Tresiba Flextouch U-200Insulin Degludec11$10,868
Metoprolol Succinate42$846
Torsemide36$723
Spironolactone90$614
Ezetimibe11$543
Potassium Chloride33$472
Warfarin Sodium43$467
Carvedilol33$319
Furosemide45$248
Atorvastatin Calcium16$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$357$87,04583 claims
NovartisEntresto$293$65,49653 claims
PfizerEliquis$173$27,45332 claims
AstraZenecaFarxiga$55$19,17718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 711 acute care providers in Alabama.

Other acute care in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →